-
More Than 30% Upside Seen For Vertex Stock On The Heels Of Phase 2 Data
Wednesday, July 19, 2017 - 9:45am | 348Read More...Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)'s stock soared 25 percent after the company reported encouraging phase 2 data. The company's three-drug cocktails showed an improvement in lung function among patients with cystic fibrosis by 9.6 percentage points or more, which was better...
-
Janney Initiates Galapagos At Buy, Sees Fair Value Of Shares At $64
Tuesday, August 30, 2016 - 12:16pm | 552Read More...Janney has initiated coverage of Galapagos NV (ADR) (NASDAQ: GLPG) with a Buy rating and fair value estimate of $64, citing potential success of Filgotinib. Galapagos has deals with Gilead Sciences, Inc. (NASDAQ: GILD) and AbbVie Inc (NYSE: ABBV) for the development of Filgotinib in inflammatory...
-
JPMorgan, Canaccord Confident That Vertex's CF Drug Will Get FDA Approval
Wednesday, May 13, 2015 - 1:55pm | 781Read More...On May 12, the FDA advisory committee recommended that the FDA approve Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) Orkambi therapy to treat cystic fibrosis. Shares of Vertex increased nearly 8 percent in pre-market trading following the announcement. The FDA advisory committee provides...
-
Gilead-Vertex Deal Has 'Low Probability' Of Happening, RBC Capital Says
Tuesday, April 21, 2015 - 12:57pm | 346Read More...In a report published Tuesday, RBC Capital Markets analyst Michael Yee commented on the increasing Street "appreciation" over the idea that Gilead Sciences, Inc. (NASDAQ: GILD) should acquire Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX). Yee noted that many investors are working...
-
Short Interest in Biotech Firms on the Rise
Monday, August 27, 2012 - 3:21pm | 571Read More...Short interest data has been released from the August 15 settlement date. Overall short sellers have continued to bet on biotech firms compared to the July 31 settlement date. A couple of notable exceptions are Alexion Pharmaceuticals (NASDAQ: ALXN) and Biogen Idec (NASDAQ: BIIB), which saw short...
-
UPDATE: Citadel Securities Initiates Coverage on Vertex
Monday, August 8, 2011 - 7:04am | 85Read More...Citadel Securities has published a report on Vertex (NASDAQ: VRTX) initiating coverage on the medicine developer. In the report, Citadel Securities wrote, "We are initiating coverage of Vertex Pharmaceuticals (VRTX) with a Neutral rating and $46 price target. While the launch of Incivek for HCV is...
-
Street Overestimating Sales of Vertex's Incivek, Morgan Stanley Reports
Thursday, June 23, 2011 - 7:35am | 48Read More...Morgan Stanley believes the Street is overestimating the sales growth trajectory of Vertex's (NASDAQ: VRTX) “novel hepatitis C (HCV) therapy, Incivek.” “We expect numbers to disappoint, especially in the early quarters of launch,” Morgan Stanley writes. Vertex closed Wednesday at $47.21.
-
Oppenheimer's Current Biotech Ratings
Monday, September 13, 2010 - 10:41am | 138Read More...Stock Prices as of September 10, 2010 Anadys Pharmaceuticals Inc. (NASDAQ: ANDS) $1.75, PERFORM BioMarin Pharmaceutical (NASDAQ: BMRN) $22.62, PERFORM Chelsea Therapeutics (NASDAQ: CHTP) $3.91, PERFORM Dynavax Technologies (NASDAQ: DVAX) $1.69, PERFORM Genzyme (NASDAQ: GENZ) $70.63, PERFORM...
